Subscribe
shutterstock_85914670_nagy_bagoly_arpad
Nagy Bagoly Arpad / Shutterstock.com
30 July 2019Big PharmaSaman Javed

Teva to pay California $69m over pay-for-delay deals

The state of California has secured a $69 million  settlement with  Teva, which allegedly entered into collusive pay-for-delay agreements with generic competitors.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
California outlaws pay-for-delay deals
9 October 2019   California has become the first US state to ban pay-for-delay deals in the pharmaceutical industry.
Americas
Endo pays $2.3m to settle states antitrust claims
22 July 2019   Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.


Editor's picks

AstraZeneca unit faces class-action suit over alleged Soliris monopoly
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

Editor's picks

Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025

More on this story

Americas
California outlaws pay-for-delay deals
9 October 2019   California has become the first US state to ban pay-for-delay deals in the pharmaceutical industry.
Americas
Endo pays $2.3m to settle states antitrust claims
22 July 2019   Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.

More on this story

Americas
California outlaws pay-for-delay deals
9 October 2019   California has become the first US state to ban pay-for-delay deals in the pharmaceutical industry.
Americas
Endo pays $2.3m to settle states antitrust claims
22 July 2019   Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.

More features

South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
Patent litigator with biotech and medical device background joins Sterlington
Resilience and the power of brands: Elisabeth Stewart-Bradley on 9/11, inclusion and the INTA presidency
Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
USPTO speeds up patent issuance amid widespread agency changes
Lathrop GPM adds portfolio management specialist